X
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Xiuqi Wang's research focuses on the discovery and development of novel small molecule inhibitors, primarily targeting protein kinases implicated in cancer. A significant portion of this work involves structure-based drug design and optimization to achieve potency and selectivity against specific kinase targets and their resistant mutations. Wang has published research on inhibitors for FLT3, a key target in acute myeloid leukemia (AML), including those effective against clinically relevant secondary mutations that confer resistance to existing therapies. Additionally, Wang has investigated inhibitors for RET kinases, targeting both wild-type and gatekeeper mutant forms, and has explored selective inhibitors for Aurora kinase B and Pyk2, with applications in preventing glucocorticoid-induced bone loss. Wang's scholarship metrics include an h-index of 5, with 11 total publications and 133 citations. Key collaborators include Yuet‐Kin Leung, Brendan Frett, Phuc Tran, and Anupreet Kharbanda, all from the University of Arkansas for Medical Sciences.
Metrics
- h-index: 6
- Publications: 11
- Citations: 139
Selected Publications
-
An unprecedented potent inhibitor of MV4-11 cells: investigations into the mechanism of action beyond FLT3 inhibition (2026)
-
Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor (2025)
-
Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective <i>via</i> Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss (2024)
-
Overcoming Secondary Mutations of Type II Kinase Inhibitors (2024)
-
An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L (2023)
-
N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants (2023)
-
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose (2022)
-
Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor (2021)
Collaboration Network
Top Collaborators
Hongyu Li
The University of Texas Health Science Center at San Antonio (US)
7 shared publications
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
- Overcoming Secondary Mutations of Type II Kinase Inhibitors
Showing 5 of 7 shared publications
Yuet‐Kin Leung
University of Arkansas for Medical Sciences
4 shared publications
In database
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants
Neil P. Shah
University of California, San Francisco (US)
4 shared publications
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- Overcoming Secondary Mutations of Type II Kinase Inhibitors
- N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants
Brendan Frett
University of Arkansas for Medical Sciences
3 shared publications
In database
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Wei Yan
University of Arkansas for Medical Sciences (US)
3 shared publications
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
- Overcoming Secondary Mutations of Type II Kinase Inhibitors
Phuc Tran
University of Arkansas for Medical Sciences
3 shared publications
In database
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Rosa Anna DeFilippis
University of California, San Francisco (US)
3 shared publications
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- Overcoming Secondary Mutations of Type II Kinase Inhibitors
- N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants
Lingtian Zhang
University of Arkansas for Medical Sciences (US)
2 shared publications
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
Naga Rajiv Lakkaniga
Scripps Research Institute (US)
2 shared publications
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
Jaideep B. Bharate
University of Arkansas for Medical Sciences
2 shared publications
In database
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
Anupreet Kharbanda
University of Arkansas for Medical Sciences
2 shared publications
In database
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
Marialuisa Moccia
University of Naples Federico II (IT)
2 shared publications
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Francesca Carlomagno
University of Naples Federico II (IT)
2 shared publications
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Gunaganti Naresh
University of Arkansas for Medical Sciences
2 shared publications
In database
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Walker A. Knauss
Massachusetts Institute of Technology (US)
2 shared publications
- Total Synthesis and Anticancer Study of (+)-Verticillin A
- Total Synthesis and Anticancer Study of (+)-Verticillin A
Similar Researchers
Based on overlapping research topics
Ahmed Shubbar
University of Arkansas at Fayetteville
Cancer Treatment and Pharmacology
Drug Transport and Resistance Mechanisms
Protein Structure and Dynamics
Luke Enemark
University of Arkansas for Medical Sciences
Drug Transport and Resistance Mechanisms
Protein Structure and Dynamics
Computational Drug Discovery Methods
Mahmoud Moradi
University of Arkansas at Fayetteville
Drug Transport and Resistance Mechanisms
Protein Structure and Dynamics
Computational Drug Discovery Methods
Jaideep B. Bharate
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Protein Structure and Dynamics
Acute Myeloid Leukemia Research
Darin Jones
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Drug Transport and Resistance Mechanisms
Computational Drug Discovery Methods
Hayley M. Sabol
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Drug Transport and Resistance Mechanisms
Bone health and treatments